Cite
HARVARD Citation
Gisslinger, H. et al. (2020). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet. 7 (3), pp. e196-e208. [Online].